Genentech Announces Six Vice President Appointments
News Jan 13, 2006
Genentech, Inc. has announced six vice president appointments: Jennifer Cook to vice president, Market Development; Ashraf Hanna, Ph.D., to vice president, Alliance Management and Pipeline Strategy Support; Ann L. Lee, Ph.D., to vice president, Process Development; James P. Miller to vice president, South San Francisco Biochemical Manufacturing; Quinton C. Oswald to vice president, Sales and Marketing, Tissue Growth and Repair; and Robert S. Quinn to vice president, CIT Business and Science Applications.
Jennifer Cook, 40, has been promoted to the newly created position of vice president, Market Development, reporting to Ian T. Clark, executive vice president, Commercial Operations.
In her new role, Cook will be responsible for managing five distinct organizations: Market Planning, Forecasting and Business Analysis, Pricing and Publication Strategy, International Operations and Commercial Communications.
Cook worked at Genentech in pre-clinical development from 1987 to 1992. She was then employed by Prizm Pharmaceuticals in product development, business development and project management before rejoining Genentech in 1997.
Since 1997, Cook has held positions of increasing responsibility in the Commercial Operations group, most recently serving as the senior director, Market Development.
Ashraf Hanna, 38, will join Genentech this month in a newly created position as vice president, Alliance Management and Pipeline Strategy Support, reporting to Susan Desmond-Hellmann, M.D., M.P.H., president, Product Development.
Working with Business Development, the Project Portfolio Management Group, and Research and Development, Hanna will be responsible for establishing, implementing and evaluating alliance management strategy and process.
Prior to joining Genentech, Hanna was vice president at Tanox, with responsibilities for strategic planning and business development.
Hanna holds a Bachelor of Arts degree in Physics from the University of Chicago, a doctorate in Physics from Harvard University and a medical degree from the University of Massachusetts Medical School.
Ann Lee, 44, joined Genentech in September 2005 as vice president, Process Development and is responsible for the development, implementation and support of clinical and commercial production processes and technologies, reporting to Patrick Y. Yang, Ph.D., executive vice president, Product Operations.
Lee joins Genentech from Merck & Company, where she held several senior leadership positions in vaccine development in the Merck Research Laboratories and served most recently, as vice president, Chemical Technology and Engineering in the manufacturing division.
Lee holds a Bachelor of Science in Chemical Engineering from Cornell University. She also earned a Master of Science in Chemical Engineering and a doctorate in Engineering and Applied Sciences from Yale University.
James Miller, 47, joined Genentech in December 2005 as vice president, South San Francisco Biochemical Manufacturing, reporting to Timothy L. Moore, vice president, South San Francisco Manufacturing.
Miller will be responsible for the production of clinical and commercial proteins using recombinant and bacterial cell technology.
Miller has held executive and senior positions at Wyeth and Chiron Corporation, as well as a variety of manufacturing positions at Invitron Corporation, Lever Brothers Company and Schering-Plough Corporation.
Miller holds a Bachelor of Science degree in Business Administration from the University of Missouri.
Quinton Oswald, 55, joined Genentech December 2005 in the newly created position of vice president, Sales and Marketing, Tissue Growth and Repair, reporting to Ian T. Clark, executive vice president, Commercial Operations.
In this role, Oswald will be responsible for sales and marketing for four distinct operating groups: Lucentis, Lytics, Nutropin and Pulmozyme.
Oswald joins Genentech from Novartis, where he held several leadership positions, including, most recently, senior vice president, Novartis Ophthalmics North America.
While at Novartis, he also held senior vice president roles in Global Marketing and Sales Operations, as well as Global Sales.
Prior, Oswald was president, Latin America and Canada Worldwide Medicines Group at Bristol-Myers Squibb. Oswald was educated in South Africa.
Robert Quinn, 49, joined Genentech in December 2005 as vice president, CIT Business and Science Applications, reporting to Todd Pierce, vice president, Corporate Information Technology.
In this newly created position, Quinn will focus on a variety of IT solutions to support the company's Corporate and Commercial Functions, and Research and Development.
Additionally, he will be responsible for building Genentech's enterprise IT systems and improving business processes.
Quinn joins Genentech from KLA-Tencor, where he served as vice president and chief information officer.
Quinn holds Bachelor of Arts degrees in Economics and Accounting from Baldwin-Wallace College.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.